Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.
Recommended CitationKurup, Drishya; Malherbe, Delphine C; Wirblich, Christoph; Lambert, Rachael; Ronk, Adam J; Zabihi Diba, Leila; Bukreyev, Alexander; and Schnell, Matthias J., "Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model." (2021). Department of Microbiology and Immunology Faculty Papers. Paper 125.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.